Unlike high expression of cyclin E1, which is predictive of poor survival, 19q12 (CCNE1) amplification had no prognostic value for overall survival in BRCA1 mutated breast cancer (Fig. 1h). This evidence concerns the gene BRCA1 and breast carcinoma.